PRISM BioLab Co.,LTD
206A・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 3 directors (including 1 outside director, an outside ratio of approximately 33%), together with 4 outside corporate auditors. Neither a Nomination Committee nor a Compensation Committee has been established. A Risk Compliance Committee has been established, meeting twice a year. The Board of Directors met 18 times during the fiscal year under review.
Risk Management
The company has established a Risk and Compliance Committee (chaired by the Representative Director, meeting twice a year), building a system in which risk and opportunity reports from each department are evaluated and prioritized by urgency and impact before being deliberated by the Board of Directors. In the event of unforeseen circumstances, a task force headed by the Representative Director is set up to minimize losses.
Shareholder Returns
No-dividend policy at this stage. Interim dividend for FY2026 (ending September 2026) is ¥0, and year-end dividend forecast is also ¥0. Priority is given to securing funds for R&D, with dividends to be considered once stable earnings are expected in the future. No share buybacks have been implemented.
Dividend Policy
Priority is given to securing funds to continue R&D activities, and no dividends are planned at this stage. The annual dividend for FY2025 (ended September 2025) was ¥0, and both the interim dividend and year-end dividend forecast for FY2026 (ending September 2026) are ¥0. The policy is to consider dividend payments in light of financial position and business performance once stable earnings can be achieved in the future.
ESG
The Board of Directors oversees sustainability, placing emphasis on social, employee, and environmental sustainability. In hiring and talent development, the company adopts a merit-based approach regardless of race, gender, or age, while on the environmental front it emphasizes compliance in the management of experimental waste. Quantitative indicators and targets have not yet been established at this time and are treated as a matter for future consideration.
Last updated: December 24, 2025